News | February 23, 2022
ACUITE upgrades ratings of Bal Pharma
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
AIIA partners with Startup India with the aim to identify and support innovations and start-ups working in the Ayush sector
Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants
Dr. Reddy’s, will focus its resources and capabilities on its key therapy spaces of gastroenterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health as the Russia and CIS region continues to be a strong performer for the company
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
Subscribe To Our Newsletter & Stay Updated
